Skip to main content

Advertisement

SpringerLink
Log in

CD151 Overexpression is Associated with Poor Prognosis in Patients with pT3 Gastric Cancer

  • Gastrointestinal Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Introduction

CD151, a transmembrane protein of the tetraspanin family, is implicated in the regulation of cell-substrate adhesion and cell migration. Overexpression of CD151 has been reported in several cancers and controls MET-dependent neoplastic growth by enhancing receptor signaling. However, association of CD151 overexpression with MET or tumor progression has not been reported in gastric cancer.

Materials and Methods

We conducted immunohistochemical analysis of CD151 overexpression in 491 pT3 gastric carcinomas and analyzed the relationship with MET overexpression and prognostic significance.

Results

CD151 was highly expressed in 119 gastric carcinomas (24.2 %) and was significantly associated with higher pN stages. Patients with CD151-positive gastric cancer showed shorter overall (p = 0.003) and disease-free survival (p = 0.001) compared with patients with CD151-negative gastric carcinoma. CD151 overexpression was an independent prognostic factor for overall survival [hazard ration (HR) 1.335; 95 % CI 1.005–1.775; p = 0.046] and disease-free survival (HR 1.903; 95 % CI 1.348–2.685; p < 0.001). Co-overexpression of CD151 and MET was observed in 30 (6.1 %) gastric cancers and was more frequent in advanced pN stages than in other groups. Moreover, co-overexpression of CD151 and MET was a strong independent prognostic factor for overall survival (HR 3.163; 95 % CI 1.958–5.108; p < 0.001) and disease-free survival (HR 3.834; 95 % CI 2.145–6.852; p < 0.001).

Conclusion

CD151 overexpression is an independent prognostic factor and could be a potential molecular therapeutic target in patients with advanced gastric cancers. Further studies are needed to establish the biological significance of CD151/MET co-overexpression and the potential of targeting both molecules as a therapeutic strategy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.

    Article  PubMed  Google Scholar 

  2. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.

    Article  CAS  PubMed  Google Scholar 

  3. Huang XY, Ke AW, Shi GM, et al. Overexpression of CD151 as an adverse marker for intrahepatic cholangiocarcinoma patients. Cancer. 2010;116:5440–51.

    Article  CAS  PubMed  Google Scholar 

  4. Yunta M, Lazo PA. Tetraspanin proteins as organisers of membrane microdomains and signalling complexes. Cell Signal. 2003;15:559–64.

    Article  CAS  PubMed  Google Scholar 

  5. Kazarov AR, Yang X, Stipp CS, Sehgal B, Hemler ME. An extracellular site on tetraspanin CD151 determines alpha 3 and alpha 6 integrin-dependent cellular morphology. J Cell Biol. 2002;158:1299–309.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Ke AW, Shi GM, Zhou J, et al. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology. 2009;49:491–503.

    Article  CAS  PubMed  Google Scholar 

  7. Hemler ME. Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Annu Rev Cell Dev Biol. 2003;19:397–422.

    Article  CAS  PubMed  Google Scholar 

  8. Romanska HM, Berditchevski F. Tetraspanins in human epithelial malignancies. J Pathol. 2011;223:4–14.

    Article  CAS  PubMed  Google Scholar 

  9. Testa JE, Brooks PC, Lin JM, Quigley JP. Eukaryotic expression cloning with an antimetastatic monoclonal antibody identifies a tetraspanin (PETA-3/CD151) as an effector of human tumor cell migration and metastasis. Cancer Res. 1999;59:3812–20.

    CAS  PubMed  Google Scholar 

  10. Tokuhara T, Hasegawa H, Hattori N, et al. Clinical significance of CD151 gene expression in non-small cell lung cancer. Clin Cancer Res. 2001;7:4109–14.

    CAS  PubMed  Google Scholar 

  11. Hashida H, Takabayashi A, Tokuhara T, et al. Clinical significance of transmembrane 4 superfamily in colon cancer. Br J Cancer. 2003;89:158–67.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Zhu GH, Huang C, Qiu ZJ, et al. Expression and prognostic significance of CD151, c-Met, and integrin alpha3/alpha6 in pancreatic ductal adenocarcinoma. Dig Dis Sci. 2011;56:1090–8.

    Article  CAS  PubMed  Google Scholar 

  13. Devbhandari RP, Shi GM, Ke AW, et al. Profiling of the tetraspanin CD151 web and conspiracy of CD151/integrin beta1 complex in the progression of hepatocellular carcinoma. PLoS One. 2011;6:e24901.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Suzuki S, Miyazaki T, Tanaka N, et al. Prognostic significance of CD151 expression in esophageal squamous cell carcinoma with aggressive cell proliferation and invasiveness. Ann Surg Oncol. 2011;18:888–93.

    Article  PubMed  Google Scholar 

  15. Yoo SH, Lee K, Chae JY, Moon KC. CD151 expression can predict cancer progression in clear cell renal cell carcinoma. Histopathology. 2011;58:191–7.

    Article  PubMed  Google Scholar 

  16. Voss MA, Gordon N, Maloney S, et al. Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer. Br J Cancer. 2011;104:1611–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Kwon MJ, Park S, Choi JY, et al. Clinical significance of CD151 overexpression in subtypes of invasive breast cancer. Br J Cancer. 2012;106:923–30.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Sadej R, Romanska H, Baldwin G, et al. CD151 regulates tumorigenesis by modulating the communication between tumor cells and endothelium. Mol Cancer Res. 2009;7:787–98.

    Article  CAS  PubMed  Google Scholar 

  19. Franco M, Muratori C, Corso S, et al. The tetraspanin CD151 is required for Met-dependent signaling and tumor cell growth. J Biol Chem. 2010;285:38756–64.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Ke AW, Shi GM, Zhou J, et al. CD151 amplifies signaling by integrin alpha6beta1 to PI3 K and induces the epithelial-mesenchymal transition in HCC cells. Gastroenterology. 2011;140:1629–41.e15.

    Google Scholar 

  21. Klosek SK, Nakashiro K, Hara S, Shintani S, Hasegawa H, Hamakawa H. CD151 forms a functional complex with c-Met in human salivary gland cancer cells. Biochem Biophys Res Commun. 2005;336:408–16.

    Article  CAS  PubMed  Google Scholar 

  22. An JY, Kim KM, Choi MG, Noh JH, Sohn TS, Bae JM, Kim S. Prognostic role of p-mTOR expression in cancer tissues and metastatic lymph nodes in pT2b gastric cancer. Int J Cancer. 2010;126:2904–13.

    CAS  PubMed  Google Scholar 

  23. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797–805.

    Article  CAS  PubMed  Google Scholar 

  24. Ha SY, Lee J, Kang SY, et al. MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. Mod Pathol. 2013. doi:10.1038/modpathol.2013.108.

    PubMed  Google Scholar 

  25. Takeda Y, Li Q, Kazarov AR, Epardaud M, Elpek K, Turley SJ, Hemler ME. Diminished metastasis in tetraspanin CD151-knockout mice. Blood. 2011;118:464–72.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Shi GM, Ke AW, Zhou J, et al. CD151 modulates expression of matrix metalloproteinase 9 and promotes neoangiogenesis and progression of hepatocellular carcinoma. Hepatology. 2010;52:183–96.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

Disclosure

None of the authors have financial relationships relevant to this publication.

Author information

Authors and Affiliations

  1. Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

    Sang Yun Ha MD, In-Gu Do MD, PhD & Kyoung-Mee Kim MD, PhD

  2. Samsung Genome Institute, Samsung Medical Center, Seoul, Korea

    In-Gu Do MD, PhD

  3. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

    Jeeyun Lee MD, PhD, Se Hoon Park MD, PhD, Joon Oh Park MD, PhD & Won Ki Kang MD, PhD

  4. Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

    Min-Gew Choi MD, PhD, Jun Ho Lee MD, PhD, Jae Moon Bae MD, PhD, Sung Kim MD, PhD & Tae Sung Sohn MD, PhD

Authors
  1. Sang Yun Ha MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. In-Gu Do MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jeeyun Lee MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Se Hoon Park MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Joon Oh Park MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Won Ki Kang MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Min-Gew Choi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jun Ho Lee MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jae Moon Bae MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Sung Kim MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kyoung-Mee Kim MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Tae Sung Sohn MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Kyoung-Mee Kim MD, PhD or Tae Sung Sohn MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ha, S.Y., Do, IG., Lee, J. et al. CD151 Overexpression is Associated with Poor Prognosis in Patients with pT3 Gastric Cancer. Ann Surg Oncol 21, 1099–1106 (2014). https://doi.org/10.1245/s10434-013-3339-1

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-013-3339-1

Keywords

Search

Navigation